-
2023-505613-24-00
4
2021-04-28
Fungal infection
-
2023-503435-17-00
5
2021-03-31
Juvenile psoriatic arthritis
-
2023-508922-83-00
10
2021-03-17
Advanced Non-Small Cell Lung Cancer
-
2024-512671-12-00
10
2021-03-05
Unresectable head and neck squamous cell carcinoma, metastatic head an
-
2023-504417-67-00
6
2020-12-22
Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Sp
-
2023-508722-99-00
4
2020-11-19
Vulvar cancer
-
2024-512526-28-00
5
2020-10-28
Locally recurrent rectal cancer
-
2024-510579-40-00
9
2020-10-07
Rhabdoyosarcoma
-
2022-501456-28-00
5
2020-07-20
atypical teratoid/rhabdoid tumours (ATRT)
-
2022-501050-11-01
10
2020-07-13
Acute Lymphoblastic Leukaemia
-
2023-506546-23-00
5
2020-05-20
Acute myeloid leukemia
-
2023-508956-20-00
5
2020-03-12
Hidradenitis suppurativa
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-509699-41-00
9
2019-11-22
Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
-
2023-507883-38-00
5
2019-11-18
Systemic Juvenile Idiopathic Arthritis
-
2023-507794-17-00
4
2019-11-11
Childhood Epilepsy
-
2024-512321-84-00
5
2019-10-02
Patients after HSCT suffering from new or reactivated CMV or EBV or Ad
-
2023-506131-15-00
5
2019-09-10
Juvenile Idiopathic Arthritis
-
2023-508101-24-00
5
2019-08-01
Lymphoblastic lymphoma
-
2024-518568-11-00
4
2019-02-04
Hematological malignancies confirmed histologically:
- AML in morphol
-
2023-506857-40-00
5
2019-01-08
Prostate Cancer
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2022-501254-10-00
5
2018-08-24
Advanced tumors